Market
Sector benefiting most from Japan's drug price cuts by end of 2024?
2
Resolution / Starting Odds
Healthcare Providers • 25%
Pharmaceutical Companies • 25%
Patients • 25%
Insurance Companies • 25%
Economic reports and analyses from Japanese financial institutions
Story
Japan Government Agrees to 2.5 Trillion Yen Drug Price Cuts, Reducing Healthcare Costs by 246.6 Billion Yen
Dec 25, 2024, 08:05 AM
The Japanese government has reached an agreement to reduce drug prices, resulting in a projected savings of 2.5 trillion yen in healthcare costs. This decision, made during ministerial negotiations, aims to alleviate the financial burden on patients by lowering official prices for nearly half of all drugs in the country. Additionally, the government plans to gradually increase the high-cost medical care system, which is expected to further impact healthcare expenses. The total reduction in healthcare costs is estimated at 246.6 billion yen as part of this initiative.
View original story
Similar markets
Other • 25%
Ozempic • 25%
Wegovy • 25%
Rybelsus • 25%
Ozempic • 25%
Other • 25%
Janumet • 25%
Wegovy • 25%
Ozempic • 25%
Wegovy • 25%
Trelegy Ellipta • 25%
Pomalyst • 25%
Pfizer • 25%
Novo Nordisk • 25%
Other • 25%
AstraZeneca • 25%
Ozempic • 25%
Wegovy • 25%
Trelegy Ellipta • 25%
Xtandi • 25%
Grocery sector • 25%
Fitness industry • 25%
Other • 25%
Healthcare sector • 25%
Cardiovascular drugs • 25%
Other • 25%
Insulin • 25%
Cancer drugs • 25%
Technology • 25%
Finance • 25%
Real Estate • 25%
Other • 25%
Consumer Goods • 25%
Technology • 25%
Healthcare • 25%
Pharmaceuticals • 25%
Ozempic • 25%
Pomalyst • 25%
Wegovy • 25%
Trelegy Ellipta • 25%
Wegovy • 25%
Other • 25%
Rybelsus • 25%
Ozempic • 25%
21% to 30% • 25%
Less than 10% • 25%
10% to 20% • 25%
More than 30% • 25%